Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5?MTA Complex for the

Smith, Christopher R.; Aranda, Ruth; Bobinski, Thomas P.; Briere, David M.; Burns, Aaron C.; Christensen, James G.; Clarine, Jeffery; Engstrom, Lars D.; Gunn, Robin J.; Ivetac, Anthony; Jean-Baptiste, Ronald; Ketcham, John M.; Kobayashi, Masakazu; Kuehler, Jon; Kulyk, Svitlana; Lawson, J.David; Moya, Krystal; Olson, Peter; Rahbaek, Lisa; Thomas, Nicole C.; Wang, Xiaolun; Waters, Laura M.; Marx, Matthew A.

doi:10.1021/acs.jmedchem.1c01900

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5?MTA Complex for the

Journal Article · 01 January 2022 · J. Med. Chem.

DOI:https://doi.org/10.1021/acs.jmedchem.1c01900· OSTI ID:1854244

Smith, Christopher R.; Aranda, Ruth; Bobinski, Thomas P.; Briere, David M.; Burns, Aaron C.; Christensen, James G.; Clarine, Jeffery; Engstrom, Lars D.; Gunn, Robin J.; Ivetac, Anthony; Jean-Baptiste, Ronald; Ketcham, John M.; Kobayashi, Masakazu; Kuehler, Jon; Kulyk, Svitlana; Lawson, J.David; Moya, Krystal; Olson, Peter; Rahbaek, Lisa; Thomas, Nicole C. more »

Research Organization:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Organization:: DOE - Office Of Science; INDUSTRY

OSTI ID:: 1854244

Journal Information:: J. Med. Chem., Vol. 65, Issue (3)

Country of Publication:: United States

Language:: ENGLISH

References (36)

Protein Arginine Methylation in Mammals: Who, What, and Why Bedford, Mark T.; Clarke, Steven G. Molecular Cell, Vol. 33, Issue 1 https://doi.org/10.1016/j.molcel.2008.12.013	journal	January 2009
Crystal structure of the human PRMT5:MEP50 complex Antonysamy, S.; Bonday, Z.; Campbell, R. M. Proceedings of the National Academy of Sciences, Vol. 109, Issue 44 https://doi.org/10.1073/pnas.1209814109	journal	October 2012
The Methylosome, a 20S Complex Containing JBP1 and pICln, Produces Dimethylarginine-Modified Sm Proteins Friesen, Westley J.; Paushkin, Sergey; Wyce, Anastasia Molecular and Cellular Biology, Vol. 21, Issue 24 https://doi.org/10.1128/MCB.21.24.8289-8300.2001	journal	December 2001
A Novel WD Repeat Protein Component of the Methylosome Binds Sm Proteins Friesen, Westley J.; Wyce, Anastasia; Paushkin, Sergey Journal of Biological Chemistry, Vol. 277, Issue 10 https://doi.org/10.1074/jbc.M109984200	journal	March 2002
Versatility of PRMT5-induced methylation in growth control and development Karkhanis, Vrajesh; Hu, Yu-Jie; Baiocchi, Robert A. Trends in Biochemical Sciences, Vol. 36, Issue 12 https://doi.org/10.1016/j.tibs.2011.09.001	journal	December 2011
PRMT5 is essential for B cell development and germinal center dynamics Litzler, Ludivine C.; Zahn, Astrid; Meli, Alexandre P. Nature Communications, Vol. 10, Issue 1 https://doi.org/10.1038/s41467-018-07884-6	journal	January 2019
Prmt5 is required for germ cell survival during spermatogenesis in mice Wang, Yanbo; Zhu, Tianxiang; Li, Qiuling Scientific Reports, Vol. 5, Issue 1 https://doi.org/10.1038/srep11031	journal	June 2015
PRMT5 Is Required for T Cell Survival and Proliferation by Maintaining Cytokine Signaling Tanaka, Yukinori; Nagai, Yasuhiro; Okumura, Mariko Frontiers in Immunology, Vol. 11 https://doi.org/10.3389/fimmu.2020.00621	journal	April 2020
Protein Arginine Methyltransferase 5 Regulates ERK1/2 Signal Transduction Amplitude and Cell Fate Through CRAF Andreu-Pérez, Pedro; Esteve-Puig, Rosaura; de Torre-Minguela, Carlos Science Signaling, Vol. 4, Issue 190 https://doi.org/10.1126/scisignal.2001936	journal	September 2011
Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency Tee, W. -W.; Pardo, M.; Theunissen, T. W. Genes & Development, Vol. 24, Issue 24 https://doi.org/10.1101/gad.606110	journal	December 2010
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells Kryukov, Gregory V.; Wilson, Frederick H.; Ruth, Jason R. Science, Vol. 351, Issue 6278 https://doi.org/10.1126/science.aad5214	journal	February 2016
MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis Marjon, Katya; Cameron, Michael J.; Quang, Phong Cell Reports, Vol. 15, Issue 3 https://doi.org/10.1016/j.celrep.2016.03.043	journal	April 2016
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 Mavrakis, Konstantinos J.; McDonald, E. Robert; Schlabach, Michael R. Science, Vol. 351, Issue 6278 https://doi.org/10.1126/science.aad5944	journal	February 2016
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity Brehmer, Dirk; Beke, Lijs; Wu, Tongfei Molecular Cancer Therapeutics, Vol. 20, Issue 12 https://doi.org/10.1158/1535-7163.MCT-21-0367	journal	September 2021
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models Chan-Penebre, Elayne; Kuplast, Kristy G.; Majer, Christina R. Nature Chemical Biology, Vol. 11, Issue 6 https://doi.org/10.1038/nchembio.1810	journal	April 2015
Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666 Duncan, Kenneth W.; Rioux, Nathalie; Boriack-Sjodin, P. Ann ACS Medicinal Chemistry Letters, Vol. 7, Issue 2 https://doi.org/10.1021/acsmedchemlett.5b00380	journal	December 2015
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity Bonday, Zahid Q.; Cortez, Guillermo S.; Grogan, Michael J. ACS Medicinal Chemistry Letters, Vol. 9, Issue 7 https://doi.org/10.1021/acsmedchemlett.8b00014	journal	April 2018
PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study. Rodon Ahnert, Jordi; Perez, Cesar Augusto; Wong, Kit Man Journal of Clinical Oncology, Vol. 39, Issue 15_suppl https://doi.org/10.1200/JCO.2021.39.15_suppl.3019	journal	May 2021
METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours Siu, L. L.; Rasco, D. W.; Vinay, S. Postel Annals of Oncology, Vol. 30 https://doi.org/10.1093/annonc/mdz244	journal	October 2019
Fragment-based lead discovery grows up Baker, Monya Nature Reviews Drug Discovery, Vol. 12, Issue 1 https://doi.org/10.1038/nrd3926	journal	December 2012
Fragment-based lead discovery: leads by design Carr, Robin A. E.; Congreve, Miles; Murray, Christopher W. Drug Discovery Today, Vol. 10, Issue 14 https://doi.org/10.1016/S1359-6446(05)03511-7	journal	July 2005
An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery Linke, Pawel; Amaning, Kwame; Maschberger, Melanie Journal of Biomolecular Screening, Vol. 21, Issue 4 https://doi.org/10.1177/1087057115618347	journal	April 2016
Biosensor-based small molecule fragment screening with biolayer interferometry Wartchow, Charles A.; Podlaski, Frank; Li, Shirley Journal of Computer-Aided Molecular Design, Vol. 25, Issue 7 https://doi.org/10.1007/s10822-011-9439-8	journal	June 2011
Fragment screening to predict druggability (ligandability) and lead discovery success Edfeldt, Fredrik N. B.; Folmer, Rutger H. A.; Breeze, Alexander L. Drug Discovery Today, Vol. 16, Issue 7-8 https://doi.org/10.1016/j.drudis.2011.02.002	journal	April 2011
Structure of the Arginine Methyltransferase PRMT5-MEP50 Reveals a Mechanism for Substrate Specificity Ho, Meng-Chiao; Wilczek, Carola; Bonanno, Jeffrey B. PLoS ONE, Vol. 8, Issue 2 https://doi.org/10.1371/journal.pone.0057008	journal	February 2013
Synthesis and characterisation of a new class of stable S-adenosyl-l-methionine salts Morana, A.; Di Lernia, I.; Cartenı̀, M. International Journal of Pharmaceutics, Vol. 194, Issue 1 https://doi.org/10.1016/S0378-5173(99)00349-X	journal	January 2000
Physiochemical drug properties associated with in vivo toxicological outcomes Hughes, Jason D.; Blagg, Julian; Price, David A. Bioorganic & Medicinal Chemistry Letters, Vol. 18, Issue 17 https://doi.org/10.1016/j.bmcl.2008.07.071	journal	September 2008
Using the Golden Triangle to optimize clearance and oral absorption Johnson, Ted W.; Dress, Klaus R.; Edwards, Martin Bioorganic & Medicinal Chemistry Letters, Vol. 19, Issue 19 https://doi.org/10.1016/j.bmcl.2009.08.045	journal	October 2009
The influence of drug-like concepts on decision-making in medicinal chemistry Leeson, Paul D.; Springthorpe, Brian Nature Reviews Drug Discovery, Vol. 6, Issue 11 https://doi.org/10.1038/nrd2445	journal	November 2007
Defining optimum lipophilicity and molecular weight ranges for drug candidates—Molecular weight dependent lower logD limits based on permeability Waring, Michael J. Bioorganic & Medicinal Chemistry Letters, Vol. 19, Issue 10 https://doi.org/10.1016/j.bmcl.2009.03.109	journal	May 2009
Revealing Atropisomer Axial Chirality in Drug Discovery LaPlante, Steven R.; Edwards, Paul J.; Fader, Lee D. ChemMedChem, Vol. 6, Issue 3 https://doi.org/10.1002/cmdc.201000485	journal	January 2011
Assessing Atropisomer Axial Chirality in Drug Discovery and Development LaPlante, Steven R.; Fader, Lee D.; Fandrick, Keith R. Journal of Medicinal Chemistry, Vol. 54, Issue 20 https://doi.org/10.1021/jm200584g	journal	September 2011
Determination of Affinity and Residence Time of Potent Drug-Target Complexes by Label-free Biosensing Quinn, John G.; Pitts, Keith E.; Steffek, Micah Journal of Medicinal Chemistry, Vol. 61, Issue 12 https://doi.org/10.1021/acs.jmedchem.7b01829	journal	May 2018
Central nervous system active compounds. XII. The synthesis and properties of 3-dimethylaminomethylene phthalides Clarke, Si; Kasum, B.; Prager, Rh Australian Journal of Chemistry, Vol. 36, Issue 12 https://doi.org/10.1071/CH9832483	journal	January 1983
Preparation and Reactions of Heteroarylmethylzinc Reagents Barl, Nadja M.; Sansiaume-Dagousset, Elodie; Monzón, Gabriel Organic Letters, Vol. 16, Issue 9 https://doi.org/10.1021/ol500790p	journal	April 2014
Oncogenic Signaling Pathways in The Cancer Genome Atlas Sanchez-Vega, Francisco; Mina, Marco; Armenia, Joshua Cell, Vol. 173, Issue 2 https://doi.org/10.1016/j.cell.2018.03.035	journal	April 2018

Similar Records

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5?MTA Complex for the

Journal Article · 2022 · J. Med. Chem. · OSTI ID:1845478

Smith, Christopher R.; Aranda, Ruth; Bobinski, Thomas P.; +20 more

Fragment optimization and elaboration strategies – the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits

Journal Article · 2022 · RSC Medicinal Chemistry · OSTI ID:2423438

Smith, Christopher R.; Kulyk, Svitlana; Ahmad, Misbha Din; +10 more

Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors

Journal Article · 2022 · Bioorganic and Medicinal Chemistry · OSTI ID:1880369

Smith, Christopher R.; Aranda, Ruth; Christensen, James G.; +12 more

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5?MTA Complex for the

Citation Formats

References (36)

Similar Records

Related Subjects